Comparison of 15- Vs. 30-Day RPM for Outpatient CAR-T-Cell Therapy Across a Large Health System
Sarah Cannon, the Cancer Institute of HCA Healthcare, and Current Health presented research findings on the effectiveness of outpatient CAR-T therapy with clinical monitoring.
The research, presented at the ASH Annual Meeting, compares clinical outcomes and adherence for 15-day versus 30-day monitoring windows in outpatient chimeric antigen receptor T-cell therapy (CAR-T) patients.
View the poster to learn how the research demonstrates that an outpatient program for patients undergoing CAR-T-cell therapy is safe, shows high patient adherence, and proposes an optimal period of monitoring that balances safety, efficiency, and patient experience.